Last update 13 Oct 2026

Paragon Biomedical, Inc.

Subsidiary Company|1989|California, United States|
www.parabio.com

Overview

Tags

Immune System Diseases
Urogenital Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody3
Top 5 TargetCount
APRIL(Tumor necrosis factor ligand superfamily member 13)1
BAFF-R(B-cell activating factor receptor)1
IFNβ(Interferon beta)1

Related

3
Drugs associated with Paragon Biomedical, Inc.
JADE-001
Target
APRIL
Mechanism
APRIL inhibitors
Active Org.
Jade Biosciences, Inc.Jade Biosciences, Inc. [+1]
Originator Org.
Jade Biosciences, Inc.Jade Biosciences, Inc.
Active Indication
Glomerulonephritis, IGA
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
JADE-201
Target
BAFF-R
Mechanism
BAFF-R inhibitors
Active Org.
Paragon Biomedical, Inc. [+1]
Originator Org.
Jade Biosciences, Inc.Jade Biosciences, Inc.
Active Indication
Rheumatoid Arthritis
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
JADE-301
Target
IFNβ
Mechanism
IFNβ inhibitors
Active Org.
Jade Biosciences, Inc.Jade Biosciences, Inc. [+1]
Originator Org.
Jade Biosciences, Inc.Jade Biosciences, Inc.
Active Indication
Dermatomyositis [+1]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Paragon Biomedical, Inc.
NCT01291901
/ CompletedPhase 2
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
NCT00710580
/ CompletedPhase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964
/ CompletedPhase 3
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
100 Clinical Results associated with Paragon Biomedical, Inc.
Login to view more data
0 Patents (Medical) associated with Paragon Biomedical, Inc.
Login to view more data
1
News (Medical) associated with Paragon Biomedical, Inc.
06 Jun 2025
Avance Clinical Appoints Mark Harvill as Chief Executive Officer
100 Deals associated with Paragon Biomedical, Inc.
Login to view more data
100 Translational Medicine associated with Paragon Biomedical, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Oct 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
1
Preclinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
JADE-001
 ( APRIL )		Glomerulonephritis, IGA
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free